Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunnybrook Health Sciences Centre
With
Canadian Association of Radiation Oncology
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Biopsy-confirmed locally recurrent prostate adenocarcinoma \> 30months after the completion of XRT, SBRT, LDR or HDR brachytherapy boost with XRT, or LDR or HDR brachytherapy as monotherapy by a stereotactic transperineal biopsy
Staging T2-weighted, DWI and DCE-MRI that demonstrates solitary recurrence confined to prostate, and correlates with stereotactic transperineal biopsy
Staging CT or MRI (abdomen and pelvis) and bone scan are negative for metastases
American Urological Association Symptom Index Score (ie. IPSS) \< 15
Baseline (post-XRT) serum PSA \< 10 ng/mL
Prostate volume as measured by transrectal ultrasound (TRUS) \< 50cc
ECOG performance status 0-1
You may not be if
Any of the following prior therapies: transurethral resection of the prostate (TURP), radionuclide (permanent or temporary implantation) prostate brachytherapy, prostatectomy or prostatic cryosurgery, HIFU (high-intensity focused ultrasound), bilateral orchiectomy, chemotherapy for prostatic carcinoma
Evidence of castrate resistance (defined as PSA \> 3 ng/mL while testosterone is \< 1.7 nmol/L). Patients could have been on combined androgen blockade with initial radiotherapy but are excluded if this was started due to PSA progression.
Clareo Health | Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer
